1. WHO | Breast cancer (2018) http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accsessed 31 Oct 2020.
2. The Israeli National Cancer registry, Breast Cancer in Israel, Update incidence and mortality data, 2018, Ministry of Health, Israel. https://www.health.gov.il/PublicationsFiles/breast_cancer_SEPT2018.pdf
3. Robson M, Offit K (2007) Management of an inherited predisposition to breast cancer. N Engl J Med 357:154–162. https://doi.org/10.1056/NEJMcp071286
4. Pilarski R, Berry MP, Jude S, et al (2019) Continue NCCN Guidelines Panel Disclosures Breast surgical oncology NCCN Guidelines Version 1.2020 Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic
5. Kamel D, Gray C, Walia JS, Kumar V (2018) PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: an update of clinical trials. Curr Drug Targets 19:21–37. https://doi.org/10.2174/1389450118666170711151518